STOCK TITAN

Solid Biosciences Inc - SLDB STOCK NEWS

Welcome to our dedicated news page for Solid Biosciences (Ticker: SLDB), a resource for investors and traders seeking the latest updates and insights on Solid Biosciences.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Solid Biosciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Solid Biosciences's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.67%
Tags
conferences
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.83%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.83%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.56%
Tags
management
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.56%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.32%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.58%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.8%
Tags
Solid Biosciences Inc

Nasdaq:SLDB

SLDB Rankings

SLDB Stock Data

391.54M
18.01M
0.79%
75.88%
2.44%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States
Charlestown

About SLDB

solid biosciences (solid) is a cambridge, ma based biotech company singularly focused on developing treatments and cures for duchenne muscular dystrophy (dmd). solid combines sharp commercial focus with world-class science to advance promising therapies and is positioned to catalyze therapeutic development across all aspects of the disease. condition-focused, our mandate is comprehensive; improving daily life for patients and attacking the roots of dmd.